Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $53.87 USD
Change Today +0.27 / 0.50%
Volume 221.1K
SAGE On Other Exchanges
Symbol
Exchange
NASDAQ GM
Frankfurt
NASDAQ GM
Berlin
As of 2:55 PM 08/31/15 All times are local (Market data is delayed by at least 15 minutes).

sage therapeutics inc (SAGE) Snapshot

Open
$53.07
Previous Close
$53.60
Day High
$54.18
Day Low
$52.06
52 Week High
06/9/15 - $89.04
52 Week Low
09/16/14 - $26.27
Market Cap
1.6B
Average Volume 10 Days
503.1K
EPS TTM
$-2.43
Shares Outstanding
28.8M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for SAGE THERAPEUTICS INC (SAGE)

sage therapeutics inc (SAGE) Related Businessweek News

No Related Businessweek News Found

sage therapeutics inc (SAGE) Details

Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes novel medicines to treat life-threatening and rare central nervous system disorders. The company’s lead product candidate includes SAGE-547, an intravenous (IV) agent that is in Phase I/II clinical development as an adjunctive therapy for the treatment of super-refractory status epilepticus (SRSE). Its pipeline also includes second-generation molecules, such as SAGE-217, an oral therapy for orphan genetic epilepsies; and SAGE-689, an adjunctive intravenous second-line therapy for the treatment of refractory status epilepticus. The company was formerly known as Sterogen Biopharma, Inc. and changed its name to Sage Therapeutics, Inc. in September 2011. Sage Therapeutics, Inc. was founded in 2010 and is based in Cambridge, Massachusetts.

35 Employees
Last Reported Date: 08/12/15
Founded in 2010

sage therapeutics inc (SAGE) Top Compensated Officers

Chief Executive Officer, President, Director ...
Total Annual Compensation: $550.0K
Chief Medical Officer
Total Annual Compensation: $390.0K
Chief Scientific Officer
Total Annual Compensation: $300.0K
Compensation as of Fiscal Year 2014.

sage therapeutics inc (SAGE) Key Developments

SAGE Therapeutics Announces First Patient Treated in Phase 3 Status Trial of SAGE-547 in Super-Refractory Status Epilepticus

SAGE Therapeutics announced that it has treated the first patient enrolled in the STATUS Trial (SAGE-547 Treatment as Adjunctive Therapy Utilized in Status Epilepticus), a global, Phase 3, randomized, double-blind, placebo-controlled clinical trial to evaluate SAGE-547 as a treatment for patients with super-refractory status epilepticus (SRSE). SRSE is a rare, life-threatening condition of persistent, unremitting seizure, for which there are no approved therapies. The STATUS Trial is designed to assess the efficacy and safety of SAGE-547 in approximately 126 patients with SRSE, aged two years or older, and will be conducted in the U.S., Canada and Europe. Patients will be randomized 1:1 to receive either SAGE-547 or placebo in addition to standard-of-care third-line anti-seizure agents for six days. The planned primary endpoint of the Phase 3 clinical trial will be successful resolution of status epilepticus (SE) after weaning the patient off all third-line agents, and SAGE-547 or placebo, without resumption of SE within 24 hours after completion of blinded SAGE-547 or placebo administration. SAGE recently announced that agreement has been reached with the U.S. Food and Drug Administration (FDA) under a Special Protocol Assessment on the trial design, endpoints and statistical approach of the Phase 3 clinical trial. The SPA provides agreement from the FDA that the Phase 3 STATUS Trial can adequately address objectives in support of a U.S. regulatory submission for approval of SAGE-547 for the treatment of patients with SRSE. SAGE's Phase 3 open-label expanded access protocol, designated Study 302, was initiated in April 2015 and continues its enrollment. Study 302 is designed to make SAGE-547 available to patients in the U.S. who are affected by SRSE and who have not been admitted to, nor can be transferred to, a planned STATUS Trial clinical site. In a completed Phase 1/2 open-label clinical trial, SAGE-547 demonstrated robust activity, with a 77% response rate in 22 evaluable patients with SRSE, and also a favorable tolerability profile. Independent of treatment response, six patient deaths occurred within the trial period, all driven by underlying conditions. Although 64% of patients reported serious adverse events, none were drug-related as determined by the Safety Review Committee.

SAGE Therapeutics Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2015

SAGE Therapeutics reported unaudited consolidated earnings results for the second quarter and six months ended June 30, 2015. For the quarter, the company reported loss from operations of $25,059 million against $6,188 million a year ago. Net loss attributable to common stockholders was $25,027 million or $0.90 per basic and diluted share against $7,769 million or $4.57 per basic and diluted share a year ago. For the six months, the company reported loss from operations of $41,956 million against $11,978 million a year ago. Net loss attributable to common stockholders was $41,898 million or $1.57 per basic and diluted share against $13,885 million or $8.28 per basic and diluted share a year ago.

SAGE Therapeutics Receives Special Protocol Assessment for Phase 3 STATUS Trial of SAGE-547 in Super-Refractory Status Epilepticus

SAGE Therapeutics announced it has reached agreement with the U.S. Food and Drug Administration (FDA) under a Special Protocol Assessment (SPA) for the STATUS Trial (SAGE-547 Treatment as Adjunctive Therapy Utilized in Status Epilepticus), a global, Phase 3, randomized, double-blind, placebo-controlled clinical trial to evaluate SAGE-547 as a treatment for patients with super-refractory status epilepticus (SRSE). The SPA provides agreement from the FDA that the Phase 3 STATUS Trial can adequately address objectives in support of a U.S. regulatory submission for approval of SAGE-547 for the treatment of patients with SRSE. SRSE is a rare, life-threatening condition of persistent, unremitting seizure, for which there are no approved therapies. The STATUS Trial is designed to assess the efficacy and safety of SAGE-547 in approximately 126 patients with SRSE, aged two years or older, and will be conducted in the U.S., Canada and Europe. Patients will be randomized 1:1 to receive either SAGE-547 or placebo in addition to standard-of-care third-line anti-seizure agents for six days. The planned primary endpoint of the Phase 3 clinical trial will be successful resolution of status epilepticus (SE) after weaning the patient off all third-line agents, and SAGE-547 or placebo, without resumption of SE within 24 hours after completion of blinded SAGE-547 or placebo administration. SAGE's Phase 3 open-label expanded access protocol, designated Study 302, was initiated in April 2015 and continues its enrollment. Study 302 is designed to make SAGE-547 available to patients in the U.S. who are affected by SRSE and who have not been admitted to, nor can be transferred to, a planned STATUS Trial clinical site. In a completed Phase 1/2 open-label clinical trial, SAGE-547 demonstrated robust activity, with a 77% response rate in 22 evaluable patients with SRSE, and also a favorable tolerability profile. Independent of treatment response, six patient deaths occurred within the trial period, all driven by underlying conditions. Although 64% of patients reported serious adverse events, none were drug-related as determined by the Safety Review Committee.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
SAGE:US $53.87 USD +0.27

SAGE Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for SAGE.
View Industry Companies
 

Industry Analysis

SAGE

Industry Average

Valuation SAGE Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 7.1x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SAGE THERAPEUTICS INC, please visit www.sagerx.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.